Log in to save to my catalogue

A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostic...

A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostic...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2293013278

A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL

About this item

Full title

A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL

Publisher

London: Nature Publishing Group UK

Journal title

Leukemia, 2020-02, Vol.34 (2), p.543-552

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Diffuse large B-cell lymphoma (DLBCL) is a disease with heterogeneous outcome. Stromal signatures have been correlated to survival in DLBCL. Their use, however, is hampered by the lack of assays for formalin-fixed paraffin-embedded material (FFPE). We constructed a lymphoma-associated macrophage interaction signature (LAMIS) interrogating features...

Alternative Titles

Full title

A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2293013278

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2293013278

Other Identifiers

ISSN

0887-6924

E-ISSN

1476-5551

DOI

10.1038/s41375-019-0573-y

How to access this item